Impact BioMedical Inc. (IBO) stock
IBONYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$3.06+0.38 (+14.18%)
Close on Oct 19, 2026Market cap $329.93MP/E –Yield –
Impact BioMedical gross margin
Gross margin is gross profit as a percentage of revenue.
Impact BioMedical's gross margin for the twelve months ending Dec 31, 2025 was -1225.0%. For fiscal 2025 it was -1225.0%.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1225.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 66.7% | – |
| Q4 FY2025 | Dec 31, 2025 | -5928.6% | – |
| Q3 FY2025 | Sep 30, 2025 | 94.4% | – |
| Q2 FY2025 | Jun 30, 2025 | 85.7% | – |
See a number that looks wrong?